1376 related articles for article (PubMed ID: 9422474)
1. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
6. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M; Al-Kgodary T
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
19. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]